MA29100B1 - Dérivés de tétrahydrochinoline substituée par 4-cycloalkyle et leur utilisation comme médicaments - Google Patents

Dérivés de tétrahydrochinoline substituée par 4-cycloalkyle et leur utilisation comme médicaments

Info

Publication number
MA29100B1
MA29100B1 MA30003A MA30003A MA29100B1 MA 29100 B1 MA29100 B1 MA 29100B1 MA 30003 A MA30003 A MA 30003A MA 30003 A MA30003 A MA 30003A MA 29100 B1 MA29100 B1 MA 29100B1
Authority
MA
Morocco
Prior art keywords
medicaments
cycloalkyl substituted
tetrahydrochinoline
derivatives
tetrahydrochinoline derivatives
Prior art date
Application number
MA30003A
Other languages
English (en)
French (fr)
Inventor
Hilmar Bischoff
Heike Gielen-Haertwig
Volkhart Li
Carsten Schmeck
Michael Thutewohl
Alexandros Vakalopoulos
Olaf Weber
Martina Wuttke
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004060997A external-priority patent/DE102004060997A1/de
Priority claimed from DE102004061000A external-priority patent/DE102004061000A1/de
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA29100B1 publication Critical patent/MA29100B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA30003A 2004-12-18 2007-06-18 Dérivés de tétrahydrochinoline substituée par 4-cycloalkyle et leur utilisation comme médicaments MA29100B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004060997A DE102004060997A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
DE102004061000A DE102004061000A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung

Publications (1)

Publication Number Publication Date
MA29100B1 true MA29100B1 (fr) 2007-12-03

Family

ID=35841894

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30003A MA29100B1 (fr) 2004-12-18 2007-06-18 Dérivés de tétrahydrochinoline substituée par 4-cycloalkyle et leur utilisation comme médicaments

Country Status (27)

Country Link
US (2) US8124775B2 (enExample)
EP (1) EP1828137B1 (enExample)
JP (1) JP5132317B2 (enExample)
KR (1) KR20070090248A (enExample)
AR (1) AR055011A1 (enExample)
AT (1) ATE555097T1 (enExample)
AU (1) AU2005315770B2 (enExample)
BR (1) BRPI0519602A2 (enExample)
CA (1) CA2591397A1 (enExample)
CU (1) CU23452B7 (enExample)
CY (1) CY1112887T1 (enExample)
DK (1) DK1828137T3 (enExample)
DO (1) DOP2005000259A (enExample)
ES (1) ES2384980T3 (enExample)
GT (1) GT200500377A (enExample)
IL (1) IL184008A (enExample)
MA (1) MA29100B1 (enExample)
MX (1) MX2007007188A (enExample)
NO (1) NO20073146L (enExample)
PE (1) PE20060767A1 (enExample)
PL (1) PL1828137T3 (enExample)
PT (1) PT1828137E (enExample)
RU (1) RU2393151C2 (enExample)
SI (1) SI1828137T1 (enExample)
TW (1) TW200635900A (enExample)
UY (1) UY29276A1 (enExample)
WO (1) WO2006063828A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005324127A1 (en) * 2004-12-18 2006-07-13 Bayer Healthcare Ag (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors
DE102006012548A1 (de) * 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituierte Chromanol-Derivate und ihre Verwendung
ATE520696T1 (de) * 2008-03-05 2011-09-15 Boehringer Ingelheim Int Tricyclische pyridinderivate, solche verbindungen enthaltende medikamente, ihre verwendung und verfahren zu ihrer herstellung
MA34007B1 (fr) 2010-02-19 2013-02-01 Boehringer Ingelheim Int Derives de pyridine tricycliques medicaments contenant ces composes leur utilisation et leur procede de preparation
US9187450B2 (en) * 2010-07-09 2015-11-17 Daiichi Sankyo Company, Limited Substituted pyridine compound
WO2012110599A1 (en) 2011-02-17 2012-08-23 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
US9150583B2 (en) 2011-08-17 2015-10-06 Boehringer Ingelheim International Gmbh Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
US9321747B2 (en) 2012-01-06 2016-04-26 Daiichi Sankyo Company, Limited Acid addition salt of substituted pyridine compound
WO2016016157A1 (en) 2014-07-30 2016-02-04 F. Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4128681A1 (de) * 1991-08-29 1993-03-04 Bayer Ag Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE19610932A1 (de) 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
DE19704244A1 (de) 1997-02-05 1998-08-06 Bayer Ag 5-Hydroxy-alkyl substituierte Phenyle
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
MA24643A1 (fr) * 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
DE19935966A1 (de) 1999-07-30 2001-02-01 Bayer Ag Verfahren zur Reduktion von Ketoalkoholen
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
DE10250687A1 (de) 2002-10-31 2004-05-13 Bayer Ag 7H-Dibenzo(b,g)(1,5)dioxocin-5-on-Derivate und ihre Verwendung
AU2005324127A1 (en) * 2004-12-18 2006-07-13 Bayer Healthcare Ag (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors

Also Published As

Publication number Publication date
PE20060767A1 (es) 2006-09-10
IL184008A0 (en) 2007-10-31
US20080255068A1 (en) 2008-10-16
GT200500377A (es) 2006-11-09
MX2007007188A (es) 2007-08-14
AU2005315770B2 (en) 2011-12-08
DOP2005000259A (es) 2006-11-15
KR20070090248A (ko) 2007-09-05
ATE555097T1 (de) 2012-05-15
AR055011A1 (es) 2007-08-01
IL184008A (en) 2012-03-29
BRPI0519602A2 (pt) 2009-02-25
JP5132317B2 (ja) 2013-01-30
CY1112887T1 (el) 2016-04-13
TW200635900A (en) 2006-10-16
EP1828137B1 (de) 2012-04-25
PL1828137T3 (pl) 2012-09-28
EP1828137A1 (de) 2007-09-05
AU2005315770A1 (en) 2006-06-22
CU23452B7 (es) 2009-12-01
NO20073146L (no) 2007-09-18
UY29276A1 (es) 2006-07-31
PT1828137E (pt) 2012-07-04
RU2393151C2 (ru) 2010-06-27
SI1828137T1 (sl) 2012-08-31
WO2006063828A1 (de) 2006-06-22
US8124775B2 (en) 2012-02-28
US20120142728A1 (en) 2012-06-07
CA2591397A1 (en) 2006-06-22
DK1828137T3 (da) 2012-07-23
RU2007127127A (ru) 2009-01-27
ES2384980T3 (es) 2012-07-16
JP2008524145A (ja) 2008-07-10

Similar Documents

Publication Publication Date Title
DK1592457T3 (da) Folat-vinblastin-konjugat som lægemiddel
MA29100B1 (fr) Dérivés de tétrahydrochinoline substituée par 4-cycloalkyle et leur utilisation comme médicaments
RS20120139A3 (en) 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
ATE467633T1 (de) 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung
FR12C0019I2 (fr) O-cyclopropyle-carboxanilides et leur utilisation comme fongicides
PT1506781E (pt) Composicao para tratamento vaginal
ATE512965T1 (de) Pyrrolopyrimidin derivate
EP1731506A4 (en) 5-HYDROXYINDOL-3-CARBOXYLATE DERIVATIVES AND THEIR USE
DE60324099D1 (de) Arzneistoffhaltiger tampon
DK1587478T3 (da) Farmaceutisk sammensætning
EP1695761A4 (en) CATALYST COMPOSITION
ATE502035T1 (de) 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
BRPI0312048A2 (pt) conjunto para redução de dobras
DK2119472T3 (da) Hud-/hårbehandlingssystem
ATE459608T1 (de) Oxopiperidinderivate, ihre herstellung und therapeutische verwendung
ATE520654T1 (de) Polypyrrol-derivate, ihre herstellung und ihre therapeutische verwendung
FR2870846B1 (fr) Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
EP1961753A4 (en) PYRAZOLOPYRIMIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR USE
ATE499351T1 (de) Aryl- und heteroaryl-ethyl-acylguanidinderivate, ihre herstellung und ihre therapeutische anwendung
MA28603B1 (fr) Composition pharmaceutique antimycobacterienne
EP1968569A4 (en) BENZOPYRANONE DERIVATIVES AND THEIR USE AS ANTI-CORONAVIRUS AGENTS
ATE474840T1 (de) 6-heteroarylpyridoindolon-derivate, ihre herstellung und ihre therapeutische anwendung
DE602005010492D1 (de) EKG-Referenzwertberechnung
ITMI20040943A1 (it) Composizione farmaceutica cicatrizzante
ATE411295T1 (de) 2h- oder 3h-benzoäeüindazol-1-yl-karbamat- derivate, herstellung und therapeutische verwendung